U.S. markets open in 7 hours 41 minutes

Annexon, Inc. (ANNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.54+0.48 (+2.28%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close21.06
Bid21.44 x 1000
Ask0.00 x 800
Day's Range20.87 - 21.78
52 Week Range17.27 - 38.01
Avg. Volume172,077
Market Cap824.092M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Moving Average Crossover Alert: Annexon (ANNX)

    Moving Average Crossover Alert: Annexon (ANNX)

    Annexon (ANNX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

  • Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth
    Simply Wall St.

    Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

  • Benzinga

    Annexon Shares Gain After Patient Dosing Starts In Mid-Stage Study For Vision Loss Disorder Therapy

    Annexon Inc (NASDAQ: ANNX) has commenced patient dosing in its Phase 2 ARCHER study evaluating ANX007 to treat Geographic Atrophy (GA). GA, also known as atrophic age-related macular degeneration (AMD) or dry AMD, can lead to blindness caused by damaged and dying retinal cells. The Phase 2 trial is designed to evaluate the efficacy and safety of ANX007. Monthly dosing schedules will be evaluated. ANX007 is a monoclonal antibody formulated for intravitreal administration. The drug candidate is designed to bind to C1q and inhibit activation of all downstream components of the classical complement cascade, including C3 and C5, but not to interfere with the normal function of C3 and C5. Price Action: ANNX shares gained 10.6% at $32.19 in market trading hours on the last check Monday. See more from BenzingaClick here for options trades from BenzingaOcular Therapeutix Shares Are Trading Higher As Company Starts Dosing In Mid-Stage Therapy Study For Dry Eye DiseaseFlexion Therapeutics To Start Testing FX301 For Post-Op Pain In Patients After Musculoskeletal Surgery© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.